Latest updates surround research trials U3-1287 and U31287, copyrightining patritumab deruxtecan for a therapy of advanced ovarian tumor. Preliminary information presented at an oncology meeting suggests some therapeutic effect, although challenges persist regarding optimal administration and patient choice. Additional evaluation is being conducted